The fine flower of scientists has just announced promising results at the largest world congress in oncology*. And French researchers appear there in a good place. Focus on the most striking discoveries.
Collon: physical activity is strong
A vast study had already shown that regular physical exercise, even moderate, decreased by 19 % to 24 % the risk of the appearance of this cancer. Directed by a researcher in Canada, Challenge, an international phase III clinical trial, shows the usefulness of a three -year program adapted, personalized and supervised by a professional to reduce the risk of recidivism of advanced or 3 stadium cancer or 3. Compared to simple recommendations made to patients, this approach improves the general form and increases the lifetime in good health. Without forgetting the pleasure: everyone chooses the activity they prefer.
Lung: immunotherapy improves survival
For the most common form of this cancer, called “not small cells”, surgery is effective in the absence of metastases, but with a high risk of relapse. The end results of the international clinical clinical trial of phase III Checkmate 816, coordinated by Pr Nicolas Girard, of the Institut Curie, confirm the performance of immunotherapy, which allows the immune system to recognize and attack cancer cells. Associated with chemotherapy before surgery, it reduces recurrences by almost 40 %. After five years, 65 % of patients treated with this association are alive (55 % for chemo alone). Professor Girard also recalls the importance of early management as well as the existence of a French screening program for smokers, the Opti-Depist-Mut study.
Sein: Salvator blood intakes
For women with metastatic hormone-dependent cancer, early detection of a treatment resistant to treatment makes it possible to add a new effective molecule, the Camizestrant: after one year, the rate of progression-free survival is more than 60 % (against 33 % in the control group). This is shown by the international phase III Serena-6 clinical trial. The Curie Institute played a major role there, both for the number of patients included and for his excellence in the detection of tumor markers in the blood. A non -invasive technique, unlike tissue biopsies.
Pancreas: the key to electric fields
It is a sneaky evil because long without symptoms and whose incidence has increased since the 1990s, to the point that it has become the sixth cause of death in cancer in the world. For those with a locally advanced form but without metastases, the Panova-3 international study has shown the interest of TTFIncs, or electric fields for the treatment of tumors. These are low -intensity electric waves designed to stop the multiplication of cancer cells. All thanks to the Novocure, non -invasive and non -toxic device: a patch placed on the skin and connected to a small generator. This treatment allows a longer life expectancy than with the only chemo. It is also studied for other cancers, including glioblastomas, aggressive brain tumors.
ENT: Treatment against relapse
Epidermoid carcinomas represent some 90 % of cancers in the head and neck. Favored by tobacco, alcohol and human papillomavirus, they attack the mucous membranes of the mouth, pharynx or larynx. Even operated, some have a high risk of recurrence, but, for the first time in twenty years, a new therapeutic weapon makes it possible to decrease it significantly: nivolumab (immunotherapy). European leader and world number 4 research in oncology, the Gustave-Roussy Institute, in Villejuif, had a key role in this international clinical trial of phase III, Nivopostop.
* Annual congress of the American clinical oncology company, in Chicago.
